Detail akcie Rocket Pharmactc Rg online

Business Summary: Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Rocket Pharmaceuticals Inc revenues was not reported. Net loss decreased 9% to $180.6M. Lower net loss reflects research and development expense balanci decrease of 17% to $98.7M (expense), General and administrative - Balancing decrease of 6% to $54.8M (expense), Stock-based Compensation in SGA decrease of 8% to $17M (expense).